TapewireFind a company

person · Reporting owner

Peraza Lisa

Disclosed activity across 2 companies

Tapewire entity
60498
SEC CIK
0001828266

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Connect Biopharma Holdings LtdCNTB · Entity 6516Senior Vice President, FinanceMarch 16, 2026March 16, 2026
HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133VP, Chief Accounting OfficerJanuary 19, 2024January 20, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Connect Biopharma Holdings Ltd

Report date March 16, 2026 · Filed March 16, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect45,189 Reported balance Holding disclosure · report date 2026-03-16 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 45,189

Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2034-08-12DirectNot disclosed Reported balance Holding disclosure · report date 2026-03-16 · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · Balance Not disclosed

F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date.

Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 · Expires 2034-12-26DirectNot disclosed Reported balance Holding disclosure · report date 2026-03-16 · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · Balance Not disclosed

F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date.

Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2035-07-07DirectNot disclosed Reported balance Holding disclosure · report date 2026-03-16 · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · Balance Not disclosed

F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date.

Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.69 · Expires 2035-12-26DirectNot disclosed Reported balance Holding disclosure · report date 2026-03-16 · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · Balance Not disclosed

F2: The stock option vests and becomes exercisable on a ratable monthly basis over four years, subject to continuous service with the Company as of each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date.

F2: The stock option vests and becomes exercisable on a ratable monthly basis over four years, subject to continuous service with the Company as of each applicable vesting date.

HERON THERAPEUTICS, INC. /DE/

Report date January 19, 2024 · Filed January 20, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.09 · Expires 2034-01-19Direct41,078 Reported balance After 2024-01-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-01-19 · Grant · Acquired 41,078 · Balance 41,078

F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (01/19/2024).

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct6,846 Reported balance After 2024-01-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2024-01-19 · Grant · Acquired 6,846 · Balance 6,846

F2: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (01/19/2024).

F2: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 19, 2024 Filed Jan 20, 2024 02:01 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 GrantRestricted Stock Units · Derivative 6,846 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-24-001977 · doc4.xml · derivative · entry 2

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,846

Underlying: Common Stock · 6,846 shares

Expires not disclosed

F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Read SEC document
January 19, 2024 Filed Jan 20, 2024 02:01 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 GrantEmployee Stock Option (Right to Buy) · Derivative 41,078 $0.00 Strike: $2.09 $0.00
Disclosure

SEC source: 0001209191-24-001977 · doc4.xml · derivative · entry 1

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,078

Underlying: Common Stock · 41,078 shares

Expires 2034-01-19

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (01/19/2024).

Read SEC document
January 13, 2024 Filed Jan 16, 2024 22:19 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,289 $0.00 $0.00
Disclosure

SEC source: 0001209191-24-001626 · doc4.xml · derivative · entry 5

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,675

Underlying: Common Stock · 1,289 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Read SEC document
January 13, 2024 Filed Jan 16, 2024 22:19 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 552 $0.00 $0.00
Disclosure

SEC source: 0001209191-24-001626 · doc4.xml · derivative · entry 4

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,656

Underlying: Common Stock · 552 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document
January 13, 2024 Filed Jan 16, 2024 22:19 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 756 $2.15 $1,625.40
Disclosure

SEC source: 0001209191-24-001626 · doc4.xml · nonDerivative · entry 3

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,907

F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
January 13, 2024 Filed Jan 16, 2024 22:19 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 1,289 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-24-001626 · doc4.xml · nonDerivative · entry 2

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,663

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
January 13, 2024 Filed Jan 16, 2024 22:19 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 552 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-24-001626 · doc4.xml · nonDerivative · entry 1

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,374

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
October 13, 2023 Filed Oct 17, 2023 23:57 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,932 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-053030 · doc4.xml · derivative · entry 8

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,964

Underlying: Common Stock · 1,932 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F5 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

F5 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Read SEC document
October 13, 2023 Filed Oct 17, 2023 23:57 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 552 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-053030 · doc4.xml · derivative · entry 7

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,208

Underlying: Common Stock · 552 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F4 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document
October 13, 2023 Filed Oct 17, 2023 23:57 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 860 $0.72 $619.20
Disclosure

SEC source: 0001209191-23-053030 · doc4.xml · nonDerivative · entry 5

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,822

F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
October 13, 2023 Filed Oct 17, 2023 23:57 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 1,932 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-053030 · doc4.xml · nonDerivative · entry 4

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,682

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
October 13, 2023 Filed Oct 17, 2023 23:57 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 552 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-053030 · doc4.xml · nonDerivative · entry 3

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
July 25, 2023 Filed Oct 17, 2023 23:57 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionPerformance Stock Units · Derivative 42,631 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-053030 · doc4.xml · derivative · entry 6

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 42,631 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On July 25, 2022, the Compensation Committee of the Issuer (the "Committee") granted the Reporting Person Performance Stock Units ("PSUs"), the vesting of which was subject to the achievement of certain corporate performance goals and time-based vesting. On January 18, 2023, the Committee determined that certain performance goals of the PSUs had been achieved. The PSUs were further subject to a time-based vesting schedule. The PSUs vested in full on the first anniversary of the grant date (July 25, 2023).

F3 · derivative.expiration_date: On July 25, 2022, the Compensation Committee of the Issuer (the "Committee") granted the Reporting Person Performance Stock Units ("PSUs"), the vesting of which was subject to the achievement of certain corporate performance goals and time-based vesting. On January 18, 2023, the Committee determined that certain performance goals of the PSUs had been achieved. The PSUs were further subject to a time-based vesting schedule. The PSUs vested in full on the first anniversary of the grant date (July 25, 2023).

Read SEC document
July 25, 2023 Filed Oct 17, 2023 23:57 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 14,743 $1.51 $22,261.93
Disclosure

SEC source: 0001209191-23-053030 · doc4.xml · nonDerivative · entry 2

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,198

F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
July 25, 2023 Filed Oct 17, 2023 23:57 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 42,631 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-053030 · doc4.xml · nonDerivative · entry 1

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,941

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
July 17, 2023 Filed Jul 19, 2023 22:21 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 GrantEmployee Stock Option (Right to Buy) · Derivative 150,000 $0.00 Strike: $1.32 $0.00
Disclosure

SEC source: 0001209191-23-042787 · doc4.xml · derivative · entry 1

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2033-07-17

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (07/17/2023).

Read SEC document
July 13, 2023 Filed Jul 17, 2023 21:51 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,933 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-042479 · doc4.xml · derivative · entry 5

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,896

Underlying: Common Stock · 1,933 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Read SEC document
July 13, 2023 Filed Jul 17, 2023 21:51 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 552 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-042479 · doc4.xml · derivative · entry 4

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,760

Underlying: Common Stock · 552 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document
July 13, 2023 Filed Jul 17, 2023 21:51 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 860 $1.31 $1,126.60
Disclosure

SEC source: 0001209191-23-042479 · doc4.xml · nonDerivative · entry 3

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,310

F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
July 13, 2023 Filed Jul 17, 2023 21:51 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 1,933 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-042479 · doc4.xml · nonDerivative · entry 2

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,170

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
July 13, 2023 Filed Jul 17, 2023 21:51 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 552 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-042479 · doc4.xml · nonDerivative · entry 1

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,237

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
April 13, 2023 Filed Apr 17, 2023 21:27 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,932 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-024498 · doc4.xml · derivative · entry 5

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,829

Underlying: Common Stock · 1,932 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Read SEC document
April 13, 2023 Filed Apr 17, 2023 21:27 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 552 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-024498 · doc4.xml · derivative · entry 4

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,312

Underlying: Common Stock · 552 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document
April 13, 2023 Filed Apr 17, 2023 21:27 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 860 $2.88 $2,476.80
Disclosure

SEC source: 0001209191-23-024498 · doc4.xml · nonDerivative · entry 3

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,685

F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
April 13, 2023 Filed Apr 17, 2023 21:27 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 1,932 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-024498 · doc4.xml · nonDerivative · entry 2

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,545

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
April 13, 2023 Filed Apr 17, 2023 21:27 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 552 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-024498 · doc4.xml · nonDerivative · entry 1

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,613

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
January 18, 2023 Filed Jan 20, 2023 22:09 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 GrantPerformance Stock Units · Derivative 42,631 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-004301 · doc4.xml · derivative · entry 1

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,631

Underlying: Common Stock · 42,631 shares

Expires not disclosed

F1 · derivative.exercise_date: On July 25, 2022, the Compensation Committee of the Issuer (the "Committee") granted the Reporting Person Performance Stock Units ("PSUs"), the vesting of which was subject to the achievement of certain corporate performance goals and time-based vesting. On January 18, 2023, the Committee determined that certain performance goals of the PSUs had been achieved. The PSUs are further subject to a time-based vesting schedule. The PSUs will vest in full on the first anniversary of the grant date subject to continued employment through such date. Upon vesting and settlement of the PSUs, the Reporting Person will receive a number of shares of common stock of the Issuer equal to the number of PSUs that have vested.

F1 · derivative.expiration_date: On July 25, 2022, the Compensation Committee of the Issuer (the "Committee") granted the Reporting Person Performance Stock Units ("PSUs"), the vesting of which was subject to the achievement of certain corporate performance goals and time-based vesting. On January 18, 2023, the Committee determined that certain performance goals of the PSUs had been achieved. The PSUs are further subject to a time-based vesting schedule. The PSUs will vest in full on the first anniversary of the grant date subject to continued employment through such date. Upon vesting and settlement of the PSUs, the Reporting Person will receive a number of shares of common stock of the Issuer equal to the number of PSUs that have vested.

Read SEC document
January 13, 2023 Filed Jan 17, 2023 22:35 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,933 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-003561 · doc4.xml · derivative · entry 5

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,761

Underlying: Common Stock · 1,933 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Read SEC document
January 13, 2023 Filed Jan 17, 2023 22:35 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 552 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-003561 · doc4.xml · derivative · entry 4

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,864

Underlying: Common Stock · 552 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document
January 13, 2023 Filed Jan 17, 2023 22:35 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 1,013 $3.17 $3,211.21
Disclosure

SEC source: 0001209191-23-003561 · doc4.xml · nonDerivative · entry 3

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,061

F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
January 13, 2023 Filed Jan 17, 2023 22:35 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 1,933 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-003561 · doc4.xml · nonDerivative · entry 2

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,074

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
January 13, 2023 Filed Jan 17, 2023 22:35 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 552 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-003561 · doc4.xml · nonDerivative · entry 1

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,141

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
October 13, 2022 Filed Oct 17, 2022 20:36 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,932 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-053832 · doc4.xml · derivative · entry 5

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,694

Underlying: Common Stock · 1,932 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Read SEC document
October 13, 2022 Filed Oct 17, 2022 20:36 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 553 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-053832 · doc4.xml · derivative · entry 4

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,416

Underlying: Common Stock · 553 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document
October 13, 2022 Filed Oct 17, 2022 20:36 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 861 $3.76 $3,237.36
Disclosure

SEC source: 0001209191-22-053832 · doc4.xml · nonDerivative · entry 3

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,589

F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
October 13, 2022 Filed Oct 17, 2022 20:36 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 1,932 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-053832 · doc4.xml · nonDerivative · entry 2

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,450

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
October 13, 2022 Filed Oct 17, 2022 20:36 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 553 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-053832 · doc4.xml · nonDerivative · entry 1

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,518

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
July 25, 2022 Filed Jul 27, 2022 22:21 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 GrantEmployee Stock Option (Right to Buy) · Derivative 60,902 $0.00 Strike: $3.17 $0.00
Disclosure

SEC source: 0001209191-22-043289 · doc4.xml · derivative · entry 1

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,902

Underlying: Common Stock · 60,902 shares

Expires 2032-07-25

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 8 equal quarterly installments beginning one quarter after the date of grant (07/25/2022).

Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:55 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,933 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-042260 · doc4.xml · derivative · entry 5

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,626

Underlying: Common Stock · 1,933 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:55 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 552 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-042260 · doc4.xml · derivative · entry 4

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,969

Underlying: Common Stock · 552 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:55 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 860 $3.01 $2,588.60
Disclosure

SEC source: 0001209191-22-042260 · doc4.xml · nonDerivative · entry 3

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,965

F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:55 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 1,933 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-042260 · doc4.xml · nonDerivative · entry 2

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,825

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:55 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 552 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-042260 · doc4.xml · nonDerivative · entry 1

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,892

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
April 13, 2022 Filed Apr 15, 2022 21:03 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,932 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-024520 · doc4.xml · derivative · entry 5

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,559

Underlying: Common Stock · 1,932 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Read SEC document
April 13, 2022 Filed Apr 15, 2022 21:03 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 552 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-024520 · doc4.xml · derivative · entry 4

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,521

Underlying: Common Stock · 552 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document
April 13, 2022 Filed Apr 15, 2022 21:03 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 860 $6.07 $5,220.20
Disclosure

SEC source: 0001209191-22-024520 · doc4.xml · nonDerivative · entry 3

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,340

F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
April 13, 2022 Filed Apr 15, 2022 21:03 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 1,932 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-024520 · doc4.xml · nonDerivative · entry 2

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
April 13, 2022 Filed Apr 15, 2022 21:03 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 552 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-024520 · doc4.xml · nonDerivative · entry 1

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,268

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
January 13, 2022 Filed Jan 14, 2022 22:06 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,933 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-003360 · doc4.xml · derivative · entry 5

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,491

Underlying: Common Stock · 1,933 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant.

F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant.

Read SEC document
January 13, 2022 Filed Jan 14, 2022 22:06 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 552 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-003360 · doc4.xml · derivative · entry 4

Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,073

Underlying: Common Stock · 552 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.